Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of Analyst/Institutional Investor Meeting under SEBI regulations, to be held on 30 July 2026 with Ventura Securities Limited. The meeting will be a virtual one-to-one meeting and will not involve the sharing of confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of Analyst/Institutional Investor Meeting under SEBI regulations, to be held on July 30, 2026, with Tamohara Investment Managers Pvt. Ltd. The meeting will be a virtual one-to-one meeting and will not involve the sharing of confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of an investor meeting with Alchemy Capital Management on July 28, 2026, to discuss publicly available information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd reported Q1 FY27 financial results, with operating revenue of INR1,671 million, a 43% year-on-year growth and 25% sequential increase. EBITDA stood at INR323 million, representing an 86% growth Y-on-Y and 15% improvement over the previous quarter.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a schedule of Analyst/Institutional Investor Meeting under SEBI regulations, to be held on 27 July 2026. The meeting will be a virtual group meeting hosted by ULJK Financial Services Pvt. Ltd. and will not involve the sharing of confidential or unpublished price-sensitive information.

Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd announced the closure of its trading window for all Designated Persons and their immediate relatives, effective from July 1, 2026. This closure is mandated by SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's code, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This is a standard compliance measure to prevent insider trading prior to financial disclosures.